MANAGEMENT OF IN-PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION

Aim. To investigate the antihypertensive effectiveness of a fixed perindopril/ amlodipine combination (Prestans) and its effects on the visit-to-visit variability of blood pressure levels and quality of life (QoL) among in-patients with uncontrolled arterial hypertension (AH).

Material and methods. The study included 35 patients (15 men and 20 women; mean age 50,4±8,9 years) who were hospitalised due to uncontrolled AH. The previously administered ineffective antihypertensive therapy was cancelled and replaced by Prestans (5/5, 10/5, 5/10, or 10/10 mg/day, subject to AH severity). The in-hospital monitoring lasted for 14 days and included daily assessment of office, systolic and diastolic BP (SBP, DBP), mean and pulse BP, intra-visit and visit- to-visit BP variability, and QoL (SF-36 questionnaire).

Results. All hospitalised patients had Stage III AH, including 31,4% with Degree 2 AH and 68,6% with Degree 3 AH. During the in-hospital course of Prestans treatment, the levels of SBP and DBP decreased from 184,2±14,6 to 142,1±13,8 mm Hg (p<0,05) and from 104,6±7,2 to 84,3±5,7 mm Hg (p<0,05), respectively. Mean and pulse BP levels also reduced significantly. The intra-visit variability of office SBP significantly decreased from Day 1 (5,07±0,9 mm Hg) to Day 14 (1,5±0,1 mm Hg; p<0.05). The visit-to-visit SBP variability also decreased, from 11,6±2,5 to - 2,1±1,2 mm Hg, respectively (p<0,01). At baseline, the patients demonstrated a substantial reduction in both physical and mental health QoL parameters. The treatment was associated with a significant improvement in the psychological health domain (emotional and social functioning).

Conclusion. In patients with uncontrolled AH, the in-hospital treatment with Prestans resulted in a mean reduction of SBP/DBP levels by 38,4/19,6 mm Hg, a significant decrease in mean and pulse BP levels, and achievement of target BP levels in 82.9% of the patients as early as at Day 14 of the treatment. The amlodipine/perindopril treatment was also associated with reduced intra-visit and visit-to-visit BP variability, as well as with improved BP control, emotional status, and QoL.

1. Powles J, Shrouft A, Mathers С, et al. National cardiovascular prevention should be

2. based on absolute disease risks, not levels of risk factors. Eur J Public Health 2010; 20:103-6.

3. The Russian medical society on an arterial hypertension (RMOAG), the All-Russian

4. Scientific Organization of Cardiologists (ARSOC). Diagnostics and treatment of arterial

5. hypertension. Russian recommendations (the fourth revision). System hypertensia 2010; 50 (3): 5-26. Russian (Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 50 (3): 5-26).

6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of

7. expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.doi: 10.1136/bmj.b1665.

8. Mancia G, Fagard R, Narkieewicz R, et al. The Task Force for the Management of Arterial Hypertension of the European society of Hypertension (EsN) and the European society of cardiology (Esc). 2013 EsN/ Esc Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-357.

9. Dahlof B, sever Ps, Poulter NR, for the AsCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (AsCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.

10. Karpov YuA, Deyev AA on behalf of participating doctors of the program "PRORYV". Uncontrollable arterial hypertension — new opportunities in a solution of the problem of efficiency of treatment. Cardiology 2012; 52 (2): 29-35. Russian (Карпов Ю.А., Деев А. А. от имени врачей-участников программы "ПРОРЫВ". Неконтролируемая артериальная гипертония — новые возможности в решении проблемы эффективности лечения. Кардиология 2012; 52 (2): 29-35).

11. Kobalava ZhD, Kotovskaya YuV on behalf of participating doctors of the program the CONsTANTA. The combined therapy of an arterial hypertension with use of the fixed combination perindopril arginin/amlodipin in real clinical practice: organization and main results of the program CONsTANTA. Cardiology 2013; 53 (6): 25-34. Russian (Кобалава Ж. Д., Котовская Ю. В. от имени врачей-участников программы КОНСТАНТА. Комбинированная терапия артериальной гипертонии с использова¬нием фиксированной комбинации периндоприла аргинина/амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология 2013; 53 (6): 25-34).

12. Questionnaire of an assessment of quality of life sF-36. (Анкета оценки качества жизни sF-36): http://atio-irk.ru/attachments/article/78/sf36.pdf.

13. www.preference-pro.com>files/sf-36 guidelines.pdf. The present instruction is prepared by the Preferense company (Настоящая инструкция подготовлена компанией "Преференсе").

14. Ostroumova OD, Barabash OL, Yakhontov DA. New opportunities in treatment of patients by an arterial hypertension in the conditions of a hospital. Results of the research DOMINANTA. Clinical pharmacology and therapy 2004; 13 (5): 16-20. Russian (Остроумова О. Д., Барабаш О. Л., Яхонтов Д. А. Новые возможности в лечении больных артериальной гипертонией в условиях стационара. Результаты исследования ДОМИНАНТА. Клиническая фармакология и терапия 2004; 13 (5): 16-20).

15. Rothwell PM, Howard sC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.

16. Mancia G, Facchetti R, Parati G, et al. Visit-to-visit blood pressure variability in the European Lacidipine study on Atherosclerosis methodological aspects and effects of antihypertensive treatment. J. Hypertens 2012; 30: 1241-51.